Somatic Mitochondrial DNA Mutations in Diffuse Large B-Cell Ly by Zeng, Andy G. X. et al.
1SCientiFiC RepoRtS |  (2018) 8:3623  | DOI:10.1038/s41598-018-21844-6
www.nature.com/scientificreports
Somatic Mitochondrial DNA 
Mutations in Diffuse Large B-Cell 
Lymphoma
Andy G. X. Zeng1, Andy C. Y. Leung2 & Angela R. Brooks-Wilson1,3
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive hematological cancer for which mitochondrial 
metabolism may play an important role. Mitochondrial DNA (mtDNA) encodes crucial mitochondrial 
proteins, yet the relationship between mtDNA and DLBCL remains unclear. We analyzed the functional 
consequences and mutational spectra of mtDNA somatic mutations and private constitutional 
variants in 40 DLBCL tumour-normal pairs. While private constitutional variants occurred frequently 
in the D-Loop, somatic mutations were randomly distributed across the mitochondrial genome. 
Heteroplasmic constitutional variants showed a trend towards loss of heteroplasmy in the 
corresponding tumour regardless of whether the reference or variant allele was being lost, suggesting 
that these variants are selectively neutral. The mtDNA mutational spectrum showed minimal support 
for ROS damage and revealed strand asymmetry with increased C > T and A > G transitions on the 
heavy strand, consistent with a replication-associated mode of mutagenesis. These heavy strand 
transitions carried higher proportions of amino acid changes – which were also more pathogenic – than 
equivalent substitutions on the light strand. Taken together, endogenous replication-associated 
events underlie mtDNA mutagenesis in DLBCL and preferentially generate functionally consequential 
mutations. Yet mtDNA somatic mutations remain selectively neutral, suggesting that mtDNA-encoded 
mitochondrial functions may not play an important role in DLBCL.
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). An 
aggressive and heterogeneous cancer, DLBCL can be categorized into multiple subtypes. The Cell of Origin 
(COO) classification system defines a germinal center B-cell type and an activated B-cell type and has prognostic 
value1. The consensus cluster classification (CCC) of molecular characteristics defines three subgroups: an oxida-
tive phosphorylation (OxPhos) group, a B-cell receptor/proliferation group and a host response group2. The fact 
that altered expression of genes involved in oxidative phosphorylation occurs frequently enough to constitute a 
subgroup suggests that mitochondrial metabolism may play an important role in DLBCL2–4.
The mitochondrial genome plays a crucial role in cellular metabolism. Each mitochondrion within the cell has 
two to ten copies of the mitochondrial genome. At 16,569 base pairs in length, it encodes 13 key subunits within 
OxPhos complexes I, III, IV and V. Given its unique genetic code, the mitochondrial genome also contains its own 
translational machinery comprising 22 tRNAs and 2 rRNAs. Mitochondrial DNA (mtDNA) is estimated to have a 
ten-fold greater mutation rate than nuclear DNA5, which has commonly been attributed to its lower DNA repair 
efficiency and greater exposure to OxPhos generated reactive oxygen species (ROS)6,7. Mutated mtDNA mole-
cules can be propagated by selection or genetic drift, ultimately constituting either a fraction of the mitochondrial 
genomes (heteroplasmy) or all of the mitochondrial genomes (homoplasmy) within a cell7.
ROS overproduction arising from deleterious mutations in OxPhos complexes has been proposed as a pri-
mary link between mtDNA and carcinogenesis in many cancers8–10. A ROS-mediated relationship may also apply 
with mtDNA and B-Cell Lymphoma. In PolgA mutator mouse models, homozygous PolgA mutants displayed a 3 
to 5 fold increase in mtDNA point mutations relative to wild-type PolgA siblings from the heterozygous parents. 
This was accompanied by reduced cytochrome c oxidase activity, increased ROS production and increased risk 
of lymphoid tumour development11. Another strain carrying a specific mtDNA mutation that impaired complex 
I activity and induced ROS overproduction also demonstrated higher risk of developing B-cell lymphoma12. 
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Administration of a ROS scavenger in these same mice reduced ROS levels in the bone marrow and prevented 
lymphoma development, further supporting a link between mtDNA, ROS and B-cell lymphoma13.
Despite these connections between mtDNA and B-Cell Lymphoma, the mutational landscape of the mito-
chondrial genome in lymphoma remains unclear. To our knowledge, mitochondrial genomes from only four 
lymphoma samples were analyzed as part of a study encompassing 31 cancer types14. The Cancer Genome 
Characterization Initiative conducted whole genome sequencing (WGS) of 40 tumour and peripheral blood 
(normal) pairs to characterize the mutational landscape in the nuclear genome of DLBCL15. We accessed this 
data through the NCBI database of Genotypes and Phenotypes (dbGaP), extracted mtDNA information and 
characterized the somatic mutations and constitutional variants in the mitochondrial genomes of the 40 DLBCL 
tumour-normal pairs.
Results
Characterization of Somatic Mutations and Private Constitutional Variants. We successfully 
extracted mitochondrial reads for 39 of the 40 tumour-normal pairs in our analysis; one pair was eliminated due 
to the absence of mitochondrial reads in the normal sample. One variant, C12705T, was present as a heteroplasmy 
in 26 samples. Inspection of the variant with the Integrative Genome Viewer16 showed that all reads containing 
C12705T also contained another variant, G12684A, which otherwise did not appear at that locus. These two var-
iants were flagged as potential artefacts and, after confirmation of their absence in corresponding RNA-seq data, 
were excluded from further analysis.
The average depth, number of total variants, number of unique variants and number of samples with one 
or more of each type of variant are shown in Table 1. A complete list of the somatic mutations can be found in 
Supplementary Table S1. Using a VAF threshold of 0.02, all samples carried constitutional variants, 34 (87%) sam-
ples carried at least one private constitutional variant, 23 (59%) carried at least one constitutional heteroplasmy 
and 29 (74%) had at least one somatic mutation in the tumour. The average read depth among called variants 
was around 2000× for all variant types. Of the 34 patients carrying private constitutional variants, the number 
of private constitutional variants per sample ranged from 1 to 7, with a mean of 3 variants per sample. Of the 29 
patients carrying somatic mutations, the number of somatic mutations per sample ranged from 1 to 5, with a 
mean of 2 mutations per sample.
From each of the 108 private constitutional variants and 60 somatic mutations, the VAF was determined; 
private constitutional variants were predominantly present as homoplasmies or low-level heteroplasmies 
(VAF < 10%), while somatic mutations were exclusively heteroplasmic and showed more variation in VAF 
(Fig. 1). The frequency of each variant within 30589 mtDNA sequences (normal and diseased) from GenBank 
showed that in comparison to private constitutional variants, somatic mutations had a significantly lower aver-
age GenBank frequency (p = 0.0043, t = −2.898). Notably, 52% of somatic mutations had not been previously 
reported in GenBank while only 7% of private constitutional variants were novel (Fig. 1).
We also assessed the distribution of private constitutional variants and somatic mutations by dividing the 
mitochondrial genome into seven functional regions: non-coding (all non-coding regions, including the 
D-Loop), rRNA (both rRNA-coding genes), tRNA (all tRNA-coding genes), OxPhos complex I (ND1, ND2, 
ND3, ND4, ND4L, ND5, ND6), complex III (CYB), complex IV (COI, COII, COIII) and complex V (ATP6, 
ATP8). The proportion of total variants within each region, as well as the percentage of the genome (by length) 
that each region constituted, is shown in Table 2. Private constitutional variants were distributed in a pattern 
distinct from that expected by chance (p = 7.81e-13, χ2 = 68.628) with a higher proportion of variants in the 
D-Loop, while the distribution of somatic mutations across the mitochondrial genome did not differ significantly 
from chance. Recurrent mutations were observed in both groups of variants: 8 positions had recurrent private 
constitutional variants (T146C, T204C, G709A, G1719A, A2905G, G12236A, G16129A, T16311C), while the 
only recurrent somatic mutation was G11711A, a non-synonymous variant in ND4 (complex I) that appeared as 
a low-level heteroplasmy in two samples.
Of the 40 somatic mutations observed in protein-coding regions, 13 (33%) were synonymous while 26 (65%) 
were non-synonymous and one was a stop-gain. In contrast, of the 59 private constitutional variants observed 
in protein-coding regions, 34 (58%) were synonymous while 25 (42%) were non-synonymous. The frequency 
of somatic mutations occurring across the three different codon positions was relatively uniform (35%, 27.5%, 
37.5%, in order of position within the codon) in comparison to that of private constitutional variants (27%, 15%, 
58%), which was notably skewed toward changes in the third (wobble) position, in which changes are mostly 
synonymous. Pathogenicity scores were obtained for non-synonymous variants using Mutpred17: Somatic muta-
tions had a higher median pathogenicity score (0.72, on a scale of 0–1) than private constitutional variants (0.49). 
Sequence depth, VAF, GenBank frequency, variant distribution, variant function and pathogenicity of somatic 










Avg Depth ± Stdev 2205 ± 1227 2237 ± 1203 2081 ± 1268 1990 ± 977
Total Variants 1006 108 40 60
Unique Variants 349 99 38 59
# of Samples 39 34 23 29
Table 1. Summary of mitochondrial variants in DLBCL sample set. Avg Depth ± Stdev = Average read depth 
and standard deviation of all variants; # of Samples = Number of samples containing one of more variant.
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To determine whether mtDNA mutations influence the clinical manifestation of DLBCL, we considered 
each patient’s tumor size, lactate dehydrogenase ratio, number of extra-nodal sites, performance status, interna-
tional prognostic index, treatment status and patient response to treatment. We found no significant association 
between mtDNA mutational burden and any of these clinical phenotypes.
Heteroplasmic Shifts. Heteroplasmic mtDNA alleles in normal tissue are expected to experience shifts in allele 
proportions through lymphomagenesis. To track such changes, the heteroplasmic fractions (HF, minor allele count/
total read count) were determined for each of the heteroplasmic constitutional alleles and their corresponding positions 
in the matched tumour sample (Fig. 2a). Heteroplasmic constitutional alleles showed a significant trend towards reduc-
tion or loss of the minor allele – represented as decreases in HF – in the corresponding tumour (p = 0.00047, t = 3.815).
Figure 1. mtDNA variants in DLBCL. Graphs from periphery to center: (1) Map of the mitochondrial genome 
(2) Average sequence depth for each position among the samples carrying variants, ranging from 0 to 4000 
reads. (3) SNVs found in DLBCL, with the height of each bar depicting the VAF. tRNA and rRNA variants are 
green, stop-gains are red, non-synonymous variants are blue, synonymous and non-coding variants are grey. 
(4) The MutPred pathogenicity score for each non-synonymous variant. (5) The log GenBank frequency of 
each variant, represented as 5 + log10(x/30589), where x is the number of genomes in GenBank that carry that 
variant. (a) Somatic Mutations in 29 samples. (b) Private constitutional variants in 34 samples.
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To understand whether these heteroplasmic shifts through lymphomagenesis are driven by selective or sto-
chastic processes, we determined variant allele fractions (VAF, variant allele count/total read count) for each 
of the heteroplasmic constitutional variants and their corresponding positions in the matched tumour sample 
(Fig. 2b). Unlike the HF trend, VAF changes were more varied and neither variant nor reference alleles were pref-
erentially fixated or lost in the corresponding tumour.
Mutational Spectrum. To understand the processes driving the formation of private constitutional variants 
and somatic mutations, we used SomaticSignatures 19 to determine the substitution frequencies in the context of 
different 5′ and 3′ nucleotides flanking the mutation site and to generate mutational spectra for mtDNA private 
constitutional variants, mtDNA somatic mutations and nuclear exonic somatic mutations (Fig. 3a). C > T substi-
tutions at CpG sites were present at the highest frequencies among nuclear somatic mutations but this was not the 
case with mtDNA variants; rather, the most frequently substituted site among both mtDNA somatic mtuations 
and private constitutional variants was GpCpT. Somatic mutations in mtDNA showed a modest elevation in the 
proportion of C > A substitutions – a signature of ROS damage19 –compared to mtDNA private constitutional 
variants (0.08 vs 0.02), but the difference was not statistically significant. Probing further into these mutational 
spectra, we determined the frequencies of different C and T substitutions occurring on the light strand (L-strand; 
forward rCRS sequence) and the heavy strand (H-strand; reverse complement of rCRS) (Fig. 3b). Among mito-
chondrial somatic mutations, there was asymmetry in the occurrence of C > T and T > C transitions for the two 
strands: C > T substitutions occurred primarily on the H-strand and T > C substitutions occurred primarily on 
the L-strand (these are equivalent to A > G on the H-strand). Notably, this strand asymmetry was more pro-
nounced among somatic mutations than private constitutional variants.
Region Genomic Length (bp) Somatic Mutation Private Constitutional
Non-Coding 1153 (7%) 4 (7%) 30 (28%)
rRNA 2513 (15%) 13 (22%) 12 (11%)
tRNA 1508 (9%) 3 (5%) 7 (6%)
Complex I 6356 (38%) 21 (35%) 35 (32%)
Complex III 1141 (7%) 2 (3%) 4 (4%)
Complex IV 3010 (18%) 13 (22%) 15 (14%)
Complex V 888 (5%) 4 (7%) 5 (5%)
Total 16519 60 108
Table 2. Variant distribution across mtDNA functional regions.
Figure 2. Shifts in heteroplasmic variant frequencies through lymphomagenesis. Constitutional variants 
identified as heteroplasmic in the normal tissue were compared to their counterpart in the matched tumour 
tissue. p values were generated by a paired t-test. (a) Changes in heteroplasmic fraction. (b) Changes in variant 
allele fraction.
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To investigate this strand asymmetry, we compared C > T and A > G variants on the H-strand with C > T and 
A > G variants on the L-strand by assessing the frequencies of non-coding, synonymous and non-synonymous 
variants (Fig. 4a) as well as the pathogenicity of non-synonymous variants (Fig. 4b). Among somatic mutations, 
C > T and A > G variants on the H-strand included a lower proportion of non-coding variants and a higher pro-
portion of non-synonymous variants than those on the L-strand. Among these non-synonymous variants, the 
pathogenicity was significantly higher for C > T and A > G variants on the H-strand compared to those on the 
L-strand. Neither of these results were reflected among private constitutional variants; instead, the proportion of 
non-coding C > T and A > G variants was modestly higher on the H-strand than the L-strand.
Discussion
A study comparing somatic mutations and constitutional variants in mtDNA of acute myeloid leukemia (AML) 
and four other cancers from the Cancer Genome Atlas (TCGA) found non-synonymous changes in 86% of 
protein-coding somatic mutations but only 31% of protein-coding constitutional variants20. Non-synonymous 
changes among somatic mutations showed higher pathogenicity than those of constitutional variants, leading 
Figure 3. Mutational spectra of mtDNA variants in DLBCL. (a) Substitution frequencies by 96 trinucleotide 
context. 108 mitochondrial private constitutional variants, 60 mitochondrial somatic mutations and 3419 
nuclear exonic somatic mutations are shown. (b) Frequency of substitution type for each mtDNA strand for 
somatic mutations and private constitutional variants.
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the authors to conclude that a higher burden of pathogenic mutations confers a selective advantage. In contrast, 
two studies using TCGA data14,21 demonstrated purifying selective pressure against deleterious and truncating 
somatic mtDNA mutations and did not observe any signs of positive selective pressures during tumourigene-
sis within the mitochondrial genome. Another study examining variants across multiple cancer types revealed 
non-random amino acid changes in cytochrome b and cytochrome c oxidase I, suggesting non-random muta-
tions across specific regions of the mitochondrial genome22. McMahon et al. used TCGA data to compare somatic 
mutations and constitutional variants in 99 breast cancer patients and noted a high frequency of variants in the 
D-Loop: somatic mutations and constitutional variants were present at 2× and 4× higher frequencies, respec-
tively, than expected by chance23.
We assessed the distribution of mtDNA variants across different functional regions of the mitochondrial 
genome (Table 2). In comparison to the variant distribution expected by chance, it is apparent that private constitu-
tional variants were subject to purifying selection, which lowered the variant load in the coding regions relative to 
the D-Loop and consequently reduced the number of potentially pathogenic variants persisting in the genome. In 
contrast, the mtDNA somatic mutation distribution is similar to that expected by chance, suggesting that somatic 
mutations are selectively neutral in DLBCL. The trend towards loss of heteroplasmy (represented by HF, Fig. 2) is 
consistent with previous reports of a tendency towards allelic fixation in cancer cells24. The lack of directionality 
in VAF changes shows that the heteroplasmic variants in the peripheral blood favour neither the fixation or loss 
of the variant allele, suggesting that these heteroplasmic shifts occur through neutral drift rather than selection. 
These heteroplasmic variants are thus unlikely to confer fitness advantages. This is consistent with the results of 
Coller et al.25, who showed that fixation of heteroplasmies into homoplasmies can occur frequently in tumours in 
the absence of any selective pressures. Taken together, these results suggest that mtDNA somatic mutations are 
tolerated by DLBCL tumours and have minimal influence on their biological and clinical characteristics.
In interpreting the mutational spectrum, we considered that 8-oxo-G damage during library preparation may 
introduce artefactual C:G > A:T substitutions that confound mutational spectrum interpretation. These variants 
are also key indicators of ROS-mediated DNA damage26, highlighting the importance of distinguishing between 
artefactual and biological G:G > A:T substitutions in order to understand the origin of mtDNA somatic muta-
tions. These library preparation artefacts primarily occur within the CCG > CAG sequence context27 and were 
detected at VAFs ranging from 0.01–0.05 in many studies of nuclear DNA28. However, given the higher copy 
number of mtDNA compared to nuclear DNA, a single 8-oxo-G insult at any position during library preparation 
would affect a relatively lower proportion of total mtDNA and the sequencing C:G > A:T artefact should manifest 
at a lower VAF than reported in nuclear DNA sequences. This is illustrated by a study of mtDNA variants present 
below 0.01 VAF, in which artefactual C:G > A:T substitutions dominated the mutational spectrum29.
Figure 4. Consequences of C > T and A > G Variants on Light Strand vs Heavy Strand. (a) Frequency of Non-
Coding, Synonymous and Non-Synonymous C > T and A > G variants by strand, for somatic mutations and 
private constitutional variants. (b) Pathogenicity of Non-Synonymous C > T and A > G variants by strand, for 
somatic mutations and private constitutional variants. p values were generated by a paired t-test.
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In contrast, we report that C:G > A:T substitutions ranged in VAF from 0.04–0.983 and only represented 
2% of private constitutional variants and 8% of mtDNA somatic mutations, with none of these substitutions 
occurring within a CCG > CAG sequence context. Given that tumor and normal mtDNA undergo similar library 
preparation protocols prior to sequencing, the higher proportion of C:G > A:T substitutions observed in somatic 
mutations compared to private constitutional variants is likely to be independent of library preparation artefacts, 
but this difference is ultimately not statistically significant and constitutes only a small proportion of somatic 
mutations in DLBCL. This suggests that ROS has a limited role in mtDNA mutagenesis and is consistent with the 
general lack of ROS-mediated DNA damage signatures in mtDNA somatic mutations reported by Kauppila and 
Stewart30 and Itsara et al.31.
There were clear distinctions between the mutational spectra of nuclear exonic somatic mutations and 
mtDNA somatic mutations (Fig. 3a). In particular, nuclear exonic mutations included a high frequency of C > T 
substitutions at CpG sites while mtDNA mutations did not, suggesting different modes of mutagenesis between 
nuclear exonic mutations and mtDNA mutations in DLBCL. We also observed preferential accumulation of 
C > T and A > G transitions on the mitochondrial DNA heavy strand among both somatic mutations and pri-
vate constitutional variants is consistent with studies of age-related mitochondrial somatic mutations in nor-
mal human tissues29,32 and it has been suggested that this strand bias may be introduced through an mtDNA 
replication-associated process14,32. Mitochondrial DNA replication starts at the H-strand origin of replication 
and uses the parental L-strand as a template; the parental H-strand remains single-stranded until the L-strand 
origin is reached33. Spontaneous deamination of C to U (retained as T) and A to hypoxanthine (retained as G), 
occurs frequently in human mtDNA34 and the single-stranded parental H-strand is even more susceptible to 
these deamination events35. The strand asymmetry we observed among both mitochondrial somatic mutations 
and private constitutional variants (Fig. 3b) lends support to this endogenous replication-associated model of 
mtDNA mutagenesis.
This model of mtDNA mutagenesis explains how C and A became minority nucleotides on the H-Strand 
over the course of mtDNA evolution and implies that the remaining C and A nucleotides on the H-strand are 
more likely to be important for mitochondrial function and consequently retained through purifying selec-
tion. This implies that C > T and A > G transitions on the H-strand generated primarily from an mtDNA 
replication-associated mechanism are more likely to be functionally consequential than other transitions. Among 
somatic mutations in DLBCL, which do not face strong selective pressures, this is the case: compared to C > T 
and A > G transitions on the L-strand, C > T and A > G transitions on the H-strand carried a higher proportion 
of amino acid changes as well as a higher mean pathogenicity score. In contrast, private constitutional variants 
are subject to purifying selection and consequently do not show any notable differences in the functional con-
sequences of C > T and A > G transitions across strands (Fig. 4). This model of mutagenesis, together with the 
difference in selective pressures, would also explain why the extent of mutational asymmetry observed among 
mtDNA somatic mutations in DLBCL was greater than that of the constitutional private variants (Fig. 3b).
In contrast with Larman et al.’s study in AML and other cancers, we do not observe any strong indication 
of positive selection on mtDNA somatic mutations20. Other studies have observed purifying selection in other 
cancer types14,21,23, but we did not find evidence for purifying selection among mtDNA somatic mutations in 
DLBCL. Rather, our data suggest that mtDNA somatic mutations in DLBCL are generally selectively neutral and 
are tolerated by the tumour. We found that mtDNA variants in both normal and tumour tissue are generated 
predominantly through endogenous mtDNA replication-associated mechanisms that are distinct from nuclear 
mutagenesis and receive minimal contribution from ROS damage. These mechanisms target minority nucleotides 
and preferentially generate functionally consequential variants that face purifying selection in normal tissue but 
only neutral drift in DLBCL. Given this, we conclude that mtDNA somatic mutations are selectively neutral in 
DLBCL despite being more likely to compromise mitochondrial function, suggesting that mtDNA encoded mito-
chondrial function may not play an important role in promoting lymphomagenesis.
Methods
Samples and Data Access. Research ethics board approval was obtained from the Simon Fraser University 
Research Ethics Board and the joint University of British Columbia – BC Cancer Agency Clinical Research Ethics 
Board. Eighty WGS BAM files constituting matched tumour-normal samples of 40 patients from the CGCI were 
obtained through dbGaP (www.ncbi.nlm.nih.gov/gap)36. The WGS data (accession number phs000532.v6.p2) 
was originally generated at the Canada’s Michael Smith Genome Sciences Centre at the BC Cancer Agency using 
the Illumina HiSeq platform and aligned to the human hg18 reference sequence37.
Variant Calling. The MitoSeek tool38 was revised (Supplementary Methods) and used to extract mitochon-
drial DNA reads from WGS BAM files of 40 tumour-normal pairs, convert the mitochondrial genome coordi-
nates from the hg18 reference to the revised Cambridge Reference Sequence (rCRS) and conduct initial variant 
calling. The following conditions were applied for each position: minimum base alignment quality (BAQ) ≥20, 
minimum mapping quality (MQ) ≥20, minimum read depth ≥100, variant allele fraction (VAF) ≥0.02, variant 
allele count (VAC) ≥10 and for which the 99.999% confidence interval of the variant allele count (assuming a 
binomial distribution) did not overlap with zero. For somatic mutations, all filters remained the same, except that 
the difference in variant alleles between the tumour and normal was required to be ≥10 in allele count and ≥0.02 
in allele fraction and the 99.999% confidence interval of the variant allele count under a binomial distribution 
did not overlap with the corresponding VAF in the normal. Variants reported by MitoSeek were further filtered 
for strand bias, in which variants were eliminated if they did not have ≥5 variant alleles called on each strand.
In analyzing mutational processes in normal tissue, we identified “private” constitutional variants, variants 
that are neither common in the population nor evolutionarily informative39–41. To identify these variants, we first 
used HaploGrep to determine the haplogroup of each sample39. From the constitutional variants, we removed 
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variants that were accounted for by the sample haplogroup (global variants) as well as mutational super hot spots 
(A16182C, A16183C, T16519C), which are polymorphisms that are not haplogroup associated but occur very 
frequently in the general population39. The remaining constitutional variants were considered private.
Variant Annotation. MutPred17 was used to predict the pathogenicity and functional consequences of 
non-synonymous variants present within the set of private constitutional variants and somatic mutations. The 
GenBank frequency of each variant was determined using MitoMaster42. At the time of this analysis, GenBank 
consisted of 30589 mitochondrial genomes.
Mutational Spectrum. Nuclear variants were obtained from the supporting information of the published 
whole genome sequence analysis of the 40 patients37. Genomic coordinates were converted from hg18 to hg19 
using the UCSC Liftover tool43; 3419 of 3424 variants were successfully converted. The compiled list of variants 
consisting of nuclear somatic mutations, mitochondrial somatic mutations and mitochondrial private consti-
tutional variants were imported into R and mutation spectrum plots with consideration to 5′ and 3′ nucleotide 
context were generated using the SomaticSignatures package44.
Statistical Analysis and Data Visualization. All statistical analysis was performed using R. Analysis of 
variant distributions across functional regions of the mitochondrial genome was performed using a chi-square 
test of homogeneity, analyses of heteroplasmic changes and relative copy number were performed using a paired 
t-test and analysis of treatment status was performed with a two-sample t-test. All p values are two-tailed. Tables 
were generated using Microsoft Excel; figures were generated using R, Circos18 and Inkscape.
Accession number. The CGCI Non-Hodgkin Lymphoma – Diffuse Large B-Cell Lymphoma project dataset 
is available through dbGaP (www.ncbi.nlm.nih.gov/gap); accession number phs000532.v6.p2.
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